VAN ECK ASSOCIATES CORP - BRAINSTORM CELL THERAPEUTICS ownership

BRAINSTORM CELL THERAPEUTICS's ticker is BCLI and the CUSIP is 10501E201. A total of 94 filers reported holding BRAINSTORM CELL THERAPEUTICS in Q4 2020. The put-call ratio across all filers is 1.49 and the average weighting 0.0%.

Quarter-by-quarter ownership
VAN ECK ASSOCIATES CORP ownership history of BRAINSTORM CELL THERAPEUTICS
ValueSharesWeighting
Q1 2021$40,000
-14.9%
10,444
+1.5%
0.00%
Q4 2020$47,000
-64.9%
10,290
+29.6%
0.00%
Q3 2020$134,000
-23.0%
7,939
-48.9%
0.00%
Q2 2020$174,00015,5460.00%
Other shareholders
BRAINSTORM CELL THERAPEUTICS shareholders Q4 2020
NameSharesValueWeighting ↓
ABNER HERRMAN & BROCK LLC 241,500$1,093,0000.17%
OCCUDO QUANTITATIVE STRATEGIES LP 90,584$410,0000.13%
EPIQ PARTNERS, LLC 10,550$48,0000.03%
Phoenix Holdings Ltd. 173,683$799,0000.02%
JACOB ASSET MANAGEMENT OF NEW YORK LLC 5,500$25,0000.02%
CFO4Life Group, LLC 12,003$54,0000.02%
HighPoint Advisor Group LLC 15,733$115,0000.01%
VOLORIDGE INVESTMENT MANAGEMENT, LLC 357,761$1,619,0000.01%
Virtu Financial LLC 24,484$111,0000.01%
ETF MANAGERS GROUP, LLC 93,902$435,0000.01%
View complete list of BRAINSTORM CELL THERAPEUTICS shareholders